Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor...
35 KB (3,403 words) - 02:24, 9 February 2024
effectiveness of everolimus in carcinoid tumors have not been established. sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated...
28 KB (2,443 words) - 17:56, 13 March 2024
(NSCLC). Sunitinib is an oral drug that inhibits the phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF. Sunitinib is used in...
51 KB (4,735 words) - 08:15, 2 January 2024
cytokine therapy (IL-2, interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear...
3 KB (333 words) - 01:07, 3 December 2023
kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent). Sugen was founded in 1991 in Redwood City, California, by veteran...
8 KB (829 words) - 07:24, 29 February 2024
randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC). Sharma...
5 KB (188 words) - 23:55, 23 January 2024
small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF...
14 KB (1,671 words) - 12:47, 23 April 2024
by Pfizer. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is likely to...
6 KB (281 words) - 20:02, 20 December 2023
Retrieved 20 July 2023. "A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma". www.clinicaltrials.gov. Retrieved...
18 KB (1,467 words) - 03:08, 19 June 2024
patients and as an anti-fatigue agent in kidney cancer patients treated with sunitinib. There is a single case report of its use in the successful treatment...
5 KB (330 words) - 17:57, 18 August 2023
inhibitor that is effective both as a senolytic and as therapy for CML. Sunitinib, an inhibitor of the receptors for FGF, PDGF and VEGF is also based on...
9 KB (1,081 words) - 04:46, 16 June 2022
tyrosine kinase inhibitor sunitinib (marketed as Sutent) can be considered.: 26 and 31 The effectiveness of imatinib and sunitinib depend on the genotype...
43 KB (4,502 words) - 05:19, 17 June 2024
MedlinePlus. Clinical trial number NCT01835158 for "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced...
21 KB (1,649 words) - 23:02, 17 April 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
31 KB (3,413 words) - 23:30, 21 June 2024
stabilizers, amiodarone, interferon alpha, tyrosine kinase inhibitors such as sunitinib Central hypothyroidism Lesions compressing the pituitary (pituitary adenoma...
79 KB (8,155 words) - 22:24, 20 June 2024
trial number NCT02231749 for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate...
47 KB (4,873 words) - 10:16, 7 June 2024
pacientes con cáncer renal de células claras metastásico tratados con Sunitinib en el servicio de Oncología del Hospital Carlos Andrade Marín en el período...
4 KB (358 words) - 13:28, 15 March 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
150 KB (15,741 words) - 10:52, 27 June 2024
erlotinib has replaced gefitinib in this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bortezomib...
20 KB (2,197 words) - 05:50, 29 November 2023
gemcitabine and mitomycin C Quinine Oxymorphone Quetiapine Bevacizumab Sunitinib Platelet aggregation inhibitors (ticlopidine, clopidogrel, and prasugrel)...
41 KB (3,902 words) - 18:11, 9 June 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
68 KB (5,993 words) - 00:22, 20 June 2024
cancer therapies, especially the tyrosine kinase inhibitors sorafenib and sunitinib, have also been associated with a high incidence of acral erythema. However...
16 KB (1,634 words) - 05:28, 24 June 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
92 KB (8,667 words) - 19:29, 28 June 2024
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib...
34 KB (3,185 words) - 21:22, 8 June 2024
removal and is causing symptoms, targeted therapy with everolimus or sunitinib can reduce symptoms and slow progression of the disease. Standard cytotoxic...
122 KB (12,753 words) - 07:35, 20 May 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
121 KB (13,791 words) - 16:50, 29 June 2024
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib...
34 KB (3,875 words) - 23:00, 9 June 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
42 KB (3,935 words) - 04:01, 30 April 2024
vinblastine, vincristine, vindesine, imatinib, irinotecan, sorafenib, sunitinib, vemurafenib, temsirolimus, anastrozole, gefitinib; azole antifungals:...
80 KB (7,814 words) - 06:16, 17 June 2024
approved within the past ten years. These treatments are: Nivolumab Axitinib Sunitinib Cabozantinib Everolimus Lenvatinib Pazopanib Bevacizumab Sorafenib Tivozanib...
100 KB (10,894 words) - 16:58, 21 April 2024